血浆磷酸化tau217识别临床前期阿尔茨海默病
该横断面队列研究纳入2916名认知正常者,评估血浆p-tau217单独或两步法(阳性后经PET或CSF确认)分类Aβ状态的价值。单独检测阳性预测值79%、准确率81%;两步法阳性预测值升至91%、准确率91%,并将PET需求降至124人。免疫分析与质谱法阳性预测值相当,但总体准确率和真阳性检出率较低。
要点
- 血浆p-tau217单独检测可有效初筛认知正常者的Aβ病理。
- 两步法(p-tau217阳性后PET/CSF确认)显著提高阳性预测值至91%。
- 两步法减少PET检测需求,但需筛查更多人以识别100例Aβ阳性者。
核心结论
- 血浆p-tau217可作为单独或两步法策略,经济、可扩展且负担小地识别临床前期AD。
研究设计与样本
- 横断面队列研究,纳入2009年6月至2024年3月来自12个国际独立观察队列的2916名认知正常参与者。
- 所有参与者均有血浆p-tau217及CSF或PET Aβ生物标志物数据。
- 另在964名参与者中比较质谱法与免疫分析法p-tau217的检测性能。
主要发现
- 参与者平均年龄66.9岁(SD 9.9),971人(33.3%)Aβ阳性,1667人(57.2%)为女性,1108人(38.1%)携带至少1个APOE ε4等位基因。
- 血浆p-tau217单独检测的阳性预测值为79%(95%CI 74-84),总体准确率为81%(95%CI 80-82)。
- 两步法 workflow 中阳性预测值升至91%(95%CI 86-95),准确率显著提高。
- 两步法需筛查677人以识别100例Aβ阳性者,而单独PET需筛查536人,但PET检测需求降至124人。
关键数值与推荐
- Aβ状态由CSF或Aβ PET生物标志物确定。
- 两步法 workflow:血浆p-tau217阳性者再经PET或CSF确认。
临床怎么用
- 血浆p-tau217可用于认知正常人群的临床前期AD初筛,减少PET或CSF检测需求。
- 两步法策略可提高阳性预测值,适用于临床前期AD试验的受试者筛选。
- 免疫分析法与质谱法阳性预测值相当,但免疫法总体准确率和真阳性检出率较低,选择检测方法时需考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. OBJECTIVE: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). EXPOSURES: Plasma p-tau217 levels measured by immunoassay. MAIN OUTCOME AND MEASURES: Aβ status, determined by CSF or Aβ PET biomarkers. RESULTS: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). CONCLUSIONS AND RELEVANCE: The findings highlight the potential of plasma p-tau217 as a stand-alone test-or when used in a sequential 2-step approach alongside PET or CSF testing-as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments.
引用
- Salvadó G, Janelidze S, Bali D, et al. Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease. JAMA Neurol. 2025. PMID: 40952756. doi:10.1001/jamaneurol.2025.3217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。